Goknur Giner

Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer

James R Whittle, Francois Vaillant, Elliot Surgenor, Antonia N Policheni, Goknur Giner, Bianca D Capaldo, Huei-Rong Chen, He K Liu, Johanna F Dekkers, Norman Sachs, Hans Clevers, Andrew Fellowes, Thomas Green, Huiling Xu, Stephen B Fox, Marco J Herold, Gordon K Smyth, Daniel HD Gray, Jane E Visvader, Geoffrey J Lindeman

Journal article  |  2020  |  CLINICAL CANCER RESEARCH

PURPOSE: Although cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly extend tumor response in patients with metasta..

Targeting triple-negative breast cancers with the Smac-mimetic birinapant

Najoua Lalaoui, Delphine Merino, Goknur Giner, Francois Vaillant, Diep Chau, Lin Liu, Tobias Kratina, Bhupinder Pal, James R Whittle, Nima Etemadi, Jean Berthelet, Julius Grasel, Cathrine Hall, Matthew E Ritchie, Matthias Ernst, Gordon K Smyth, David L Vaux, Jane E Visvader, Geoffrey J Lindeman, John Silke

Journal article  |  2020  |  Cell Death and Differentiation

Smac mimetics target inhibitor of apoptosis (IAP) proteins, thereby suppressing their function to facilitate tumor cell death. Her..

qtQDA: quantile transformed quadratic discriminant analysis for high-dimensional RNA-seq data

Necla Kochan, G Yazgi Tutuncu, Gordon K Smyth, Luke C Gandoffo, Goeknur Giner

Journal article  |  2019  |  PEERJ

Classification on the basis of gene expression data derived from RNA-seq promises to become an important part of modern medicine. ..

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

Delphine Merino, James R Whittle, Francois Vaillant, Antonin Serrano, Jia-Nan Gong, Goknur Giner, Ana Leticia Maragno, Maia Chanrion, Emilie Schneider, Bhupinder Pal, Xiang Li, Grant Dewson, Julius Grasel, Kevin Liu, Najoua Lalaoui, David Segal, Marco J Herold, David CS Huang, Gordon K Smyth, Olivier Geneste, et al.

Journal article  |  2017  |  SCIENCE TRANSLATIONAL MEDICINE

The development of BH3 mimetics, which antagonize prosurvival proteins of the BCL-2 family, represents a potential breakthrough in..

RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers

GJ Lindeman, E Nolan, F Vaillant, D Branstetter, B Pal, G Giner, L Whitehead, SW Lok, GB Mann, K Rohrbach, L-Y Huang, R Soriano, GK Smyth, WC Dougall, JE Visvader

Conference Proceedings  |  2017  |  CANCER RESEARCH

Abstract Background: BRCA1 mutation carriers commonly undergo prophylactic mastectomy to reduce their risk of breas..